Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

464 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice.
Slamanig S, González-Domínguez I, Chang LA, Lemus N, Lai TY, Martínez JL, Singh G, Dolange V, Abdeljawad A, Kowdle S, Noureddine M, Warang P, Singh G, Lee B, García-Sastre A, Krammer F, Schotsaert M, Palese P, Sun W. Slamanig S, et al. Among authors: palese p. EBioMedicine. 2024 Jul;105:105185. doi: 10.1016/j.ebiom.2024.105185. Epub 2024 Jun 7. EBioMedicine. 2024. PMID: 38848648 Free PMC article.
Prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine.
Rathnasinghe R, Salvatore M, Zheng H, Jangra S, Kehrer T, Mena I, Schotsaert M, Muster T, Palese P, García-Sastre A. Rathnasinghe R, et al. Among authors: palese p. bioRxiv [Preprint]. 2021 Apr 28:2021.04.28.441797. doi: 10.1101/2021.04.28.441797. bioRxiv. 2021. Update in: Sci Rep. 2021 Nov 12;11(1):22164. doi: 10.1038/s41598-021-01780-8 PMID: 33948589 Free PMC article. Updated. Preprint.
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial.
Pitisuttithum P, Luvira V, Lawpoolsri S, Muangnoicharoen S, Kamolratanakul S, Sivakorn C, Narakorn P, Surichan S, Prangpratanporn S, Puksuriwong S, Lamola S, Mercer LD, Raghunandan R, Sun W, Liu Y, Carreño JM, Scharf R, Phumratanaprapin W, Amanat F, Gagnon L, Hsieh CL, Kaweepornpoj R, Khan S, Lal M, McCroskery S, McLellan J, Mena I, Meseck M, Phonrat B, Sabmee Y, Singchareon R, Slamanig S, Suthepakul N, Tcheou J, Thantamnu N, Theerasurakarn S, Tran S, Vilasmongkolchai T, White JA, Garcia-Sastre A, Palese P, Krammer F, Poopipatpol K, Wirachwong P, Hjorth R, Innis BL. Pitisuttithum P, et al. Among authors: palese p. medRxiv [Preprint]. 2021 Sep 22:2021.09.17.21263758. doi: 10.1101/2021.09.17.21263758. medRxiv. 2021. Update in: EClinicalMedicine. 2022 Mar 08;45:101323. doi: 10.1016/j.eclinm.2022.101323 PMID: 34580673 Free PMC article. Updated. Preprint.
Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico.
Ponce-de-León S, Torres M, Soto-Ramírez LE, Calva JJ, Santillán-Doherty P, Carranza-Salazar DE, Carreño JM, Carranza C, Juárez E, Carreto-Binaghi LE, Ramírez-Martínez L, Paz-De la Rosa G, Vigueras-Moreno R, Ortiz-Stern A, López-Vidal Y, Macías AE, Torres-Flores J, Rojas-Martínez O, Suárez-Martínez A, Peralta-Sánchez G, Kawabata H, González-Domínguez I, Martínez-Guevara JL, Sun W, Sarfati-Mizrahi D, Soto-Priante E, Chagoya-Cortés HE, López-Macías C, Castro-Peralta F, Palese P, García-Sastre A, Krammer F, Lozano-Dubernard B. Ponce-de-León S, et al. Among authors: palese p. medRxiv [Preprint]. 2022 Feb 9:2022.02.08.22270676. doi: 10.1101/2022.02.08.22270676. medRxiv. 2022. PMID: 35169806 Free PMC article. Preprint.
Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in mice.
González-Domínguez I, Martínez JL, Slamanig S, Lemus N, Liu Y, Lai TY, Carreño JM, Singh A G, Singh B G, Schotsaert M, Mena I, McCroskery S, Coughlan L, Krammer F, García-Sastre A, Palese P, Sun W. González-Domínguez I, et al. Among authors: palese p. bioRxiv [Preprint]. 2022 Mar 22:2022.03.21.485247. doi: 10.1101/2022.03.21.485247. bioRxiv. 2022. Update in: Microbiol Spectr. 2022 Jun 29;10(3):e0153822. doi: 10.1128/spectrum.01538-22 PMID: 35350201 Free PMC article. Updated. Preprint.
The immunodominance of antigenic site Sb on the H1 influenza virus hemagglutinin increases with high immunoglobulin titers of the cohorts and with young age, but not sex.
Martínez JL, Lemus N, Lai TY, Mishra M, González-Domínguez I, Puente-Massaguer E, Loganathan M, Francis B, Samanovic MI, Krammer F, Mulligan MJ, Simon V, Palese P, Sun W. Martínez JL, et al. Among authors: palese p. Vaccine. 2024 May 22;42(14):3365-3373. doi: 10.1016/j.vaccine.2024.04.037. Epub 2024 Apr 15. Vaccine. 2024. PMID: 38627145 Free article.
A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein.
Bliss CM, Nachbagauer R, Mariottini C, Cuevas F, Feser J, Naficy A, Bernstein DI, Guptill J, Walter EB, Berlanda-Scorza F, Innis BL, García-Sastre A, Palese P, Krammer F, Coughlan L. Bliss CM, et al. Among authors: palese p. EBioMedicine. 2024 Jun;104:105153. doi: 10.1016/j.ebiom.2024.105153. Epub 2024 May 27. EBioMedicine. 2024. PMID: 38805853 Free PMC article. Clinical Trial.
Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate AVX/COVID-12 activates T cells and is recognized by antibodies from COVID-19 patients and vaccinated individuals.
Torres-Flores A, Ontiveros-Padilla LA, Madera-Sandoval RL, Tepale-Segura A, Gajón-Martínez J, Rivera-Hernández T, Ferat-Osorio EA, Cérbulo-Vázquez A, Arriaga-Pizano LA, Bonifaz L, Paz-De la Rosa G, Rojas-Martínez O, Suárez-Martínez A, Peralta-Sánchez G, Sarfati-Mizrahi D, Sun W, Chagoya-Cortés HE, Palese P, Krammer F, García-Sastre A, Lozano-Dubernard B, López-Macías C. Torres-Flores A, et al. Among authors: palese p. Front Immunol. 2024 May 30;15:1394114. doi: 10.3389/fimmu.2024.1394114. eCollection 2024. Front Immunol. 2024. PMID: 38873610 Free PMC article.
Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 "Patria" recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico.
López-Macías C, Torres M, Armenta-Copca B, Wacher NH, Castro-Castrezana L, Colli-Domínguez AA, Rivera-Hernández T, Torres-Flores A, Damián-Hernández M, Ramírez-Martínez L, la Rosa GP, Rojas-Martínez O, Suárez-Martínez A, Peralta-Sánchez G, Carranza C, Juárez E, Zamudio-Meza H, Carreto-Binaghi LE, Viettri M, Romero-Rodríguez D, Palencia A, Reyna-Rosas E, Márquez-García JE, Sarfati-Mizrahi D, Sun W, Chagoya-Cortés HE, Castro-Peralta F, Palese P, Krammer F, García-Sastre A, Lozano-Dubernard B. López-Macías C, et al. Among authors: palese p. Vaccine. 2025 Jan 1;43(Pt 2):126511. doi: 10.1016/j.vaccine.2024.126511. Epub 2024 Nov 10. Vaccine. 2025. PMID: 39527880 Free article. Clinical Trial.
464 results